80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]吳梅梅,王靖雯,魏麗麗,等.原發(fā)性肝細(xì)胞性肝癌患者術(shù)后癌旁組織CXCR4表達(dá)的影響因素與術(shù)后生存時間[J].福建醫(yī)藥雜志,2023,45(02):8-11.
　WU Meimei,WANG Jingwen,WEI Lili,et al.Study on the influencing factors of CXCR4 expression in paracancerous tissue and postoperative survival time in patients with primary hepatocellular carcinoma after surgery[J].FUJIAN MEDICAL JOURNAL,2023,45(02):8-11.
點(diǎn)擊復(fù)制

原發(fā)性肝細(xì)胞性肝癌患者術(shù)后癌旁組織CXCR4表達(dá)的影響因素與術(shù)后生存時間()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期數(shù):
2023年02期
頁碼:
8-11
欄目:
臨床研究
出版日期:
2023-04-15

文章信息/Info

Title:
Study on the influencing factors of CXCR4 expression in paracancerous tissue and postoperative survival time in patients with primary hepatocellular carcinoma after surgery
文章編號:
1002-2600(2023)02-0008-04
作者:
吳梅梅; 王靖雯; 魏麗麗; 黃富妹; 黃警; 鄭益武; 朱琪1
福建省福州市第二醫(yī)院感控科（福州 350007）
Author(s):
WU Meimei;  WANG Jingwen;  WEI Lili;  HUANG Fumei;  HUANG Jing;  ZHENG Yiwu;  ZHU Qi
Department of Infection Control, Fuzhou Municipal Second Hospital，F(xiàn)uzhou，F(xiàn)ujian 350007，China
關(guān)鍵詞:
原發(fā)性肝癌; 癌旁組織; CXCR4; 生存期
Keywords:
primary hepatocellular carcinoma;  paracancerous tissue;  CXCR4;  survival
分類號:
R735.7
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探究原發(fā)性肝細(xì)胞性肝癌患者術(shù)后癌旁組織中CXCR4表達(dá)情況的影響因素與術(shù)后生存時間。方法收集34例原發(fā)性肝細(xì)胞性肝癌手術(shù)病例的一般情況及臨床特征并進(jìn)行定期隨訪。使用免疫組織化學(xué)法檢測原發(fā)性肝細(xì)胞性肝癌患者的癌組織及癌旁組織中CXCR4的表達(dá)情況。比較癌旁組織CXCR4不同表達(dá)時的一般情況及臨床指征；利用Kaplan-Meier法繪制生存曲線，Log-rank檢驗(yàn)進(jìn)行不同癌旁組織CXCR4表達(dá)的術(shù)后生存率的比較。結(jié)果 隨訪截至2022年6月，19例癌旁組織CXCR4陽性表達(dá)患者中死亡8例，17例癌旁組織CXCR4陰性表達(dá)患者中死亡1例。有HBsAg攜帶、Child分級B級以及有飲酒史的肝癌患者，術(shù)后癌旁組織中CXCR4的陽性表達(dá)率較高，差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。癌旁組織CXCR4陽性患者術(shù)后生存率低于陰性患者（Log-rank χ2=5.89，P=0.015）。結(jié)論 術(shù)后癌旁組織CXCR4的表達(dá)情況對原發(fā)性肝細(xì)胞性肝癌術(shù)后患者的預(yù)后有影響。
Abstract:
Objective To investigate the influencing factors of CXCR4 expression in paracancerous tissue and postoperative survival time in patients with primary hepatocellular carcinoma after surgery. Methods The general information and clinical characteristics of 34 cases of primary hepatocellular carcinoma were collected and followed up regularly. The expression of CXCR4 in cancer and paracancerous tissues of patients with primary hepatocellular carcinoma was detected by immunohistochemical method. The patients were divided into two groups according to different expression of CXCR4 in paracancerous tissues. Survival rates were calculated by using the Kaplan-Meier method and compared by using the Log-rank test. Results The follow-up ended in June 2022. Eight of the 19 patients with positive CXCR4 expression in paracancerous tissues died, and one of the 17 patients with CXCR4 negative expression in paracancerous tissues died. Patients with HBsAg carriage, Child grade B, and a history of alcohol consumption had higher positive expression of CXCR4 in postoperative paracancerous tissues, and all these differences were statistically significant (P<0.05). The survival rate of patients with positive CXCR4 expression in paracancerous tissues was lower than that of patients with negative CXCR4 expression (Log-rank χ2=5.89, P=0.015）. Conclusion The expression of CXCR4 in paracancerous tissue has an impact on the prognosis of patients with primary hepatocellular carcinoma after surgery.

參考文獻(xiàn)/References:

[1] Sung H,Ferlay J,Siegel R L,et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA：A Cancer Journal for Clinicians,2021,70（4）：313.
[2] 馬莉,楊文娟,馬青梅,等.CXCL家族作為肝癌微環(huán)境預(yù)后與治療標(biāo)志物的生物信息學(xué)分析[J].暨南大學(xué)學(xué)報(bào)：自然科學(xué)與醫(yī)學(xué)版,2022,43（1）：29-42.
[3] 張敏,張紅河,來茂德.腫瘤免疫編輯中腫瘤微環(huán)境的變化[J].中華病理學(xué)雜志,2021,50（9）：1098-1102.
[4] Nagarsheth N,Wicha M S,Zou W.Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy[J].Nat Rev Immunol,2017,17（9）：559-572.
[5] Bhoori S,Mazzaferro V.Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma：a step forward[J].The Lancet Oncology,2020,21（6）：740-741.
[6] 徐鳴,全培青,王秋梅,等.血清CXCL12及其受體CXCR4,CXCR7水平對宮頸癌復(fù)發(fā)的預(yù)測價值[J].檢驗(yàn)醫(yī)學(xué)與臨床,2022,19（8）：1065-1069.
[7] Liu P,Ping L,Yu H,et al.CXCL12/CXCR4 axis induces proliferation and invasion in human endometrial cancer[J].Am J Transl Res,2016,8（4）：1719-1729.
[8] Gao P T,Ding G Y,Yang X,et al.Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4[J].Am J Cancer Res,2018,8（6）：1040-1049.
[9] 孫牧男,劉磊,馬寅芙,等.CXCL12/CXCR4在小細(xì)胞肺癌患者中的表達(dá)及臨床意義[J].中國實(shí)驗(yàn)診斷學(xué),2015,19（1）：50-53.
[10] 王森,落繼先,Istvan Boldogh.CXCL12-CXCR4在人類惡性腫瘤中的生物學(xué)功能（英文）[J].中國生物化學(xué)與分子生物學(xué)報(bào),2022,8（5）：577-586.
[11] 謝永麗,湯華.YTHDF1對HBV蛋白表達(dá)和HBsAg和HBeAg抗原分泌的作用[J].天津醫(yī)科大學(xué)學(xué)報(bào),2021,27（5）：461-466.
[12] 孫冬雪,楊柱,龍奉璽,等.基于酒傷理論探討肝癌癌前病變中醫(yī)治療[J].遼寧中醫(yī)藥大學(xué)學(xué)報(bào),2020,22（6）：56-60.
[13] Byrne S,Boyle T,Ahmed M,et al.Lifestyle,genetic risk and incidence of cancer：a prospective cohort study of 13 cancer types[J].Int J Epidemiol,2023：dyac238.
[14] 蔣建強(qiáng).術(shù)前Child分級、微血管侵犯與原發(fā)性肝癌同種異體肝移植患者預(yù)后的相關(guān)性[J].中國衛(wèi)生工程學(xué),2020,19（5）：775-776.
[15] Chatterjee S,Azad B B,Nimmagadda S.The intricate role of CXCR4 in cancer[J].Adv Cancer Res,2014,124：31-82.
[16] Alsayed R K M E,Khan A Q,Ahmad F,et al.Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression[J].Semin Cancer Biol,2022,86（Pt 2）：697-708.
[17] 唐超莉.CXCR4表達(dá)與三陰性乳腺癌的相關(guān)性研究[J].中國當(dāng)代醫(yī)藥,2020,27（19）：118-121.
[18] Moreno M J,Bosch R,Dieguez-Gonzalez R,等.CXCR4表達(dá)可增強(qiáng)彌漫大B細(xì)胞淋巴瘤的播散能力并降低患者生存期[J].臨床與實(shí)驗(yàn)病理學(xué)雜志,2015,31（10）：1122.
[19] 唐文龍.CXCL12/CXCR4在膠質(zhì)瘤中的表達(dá)情況及其與復(fù)發(fā)、瘤周水腫的關(guān)系[D].福州：福建醫(yī)科大學(xué),2016.

相似文獻(xiàn)/References:

[1]楊蔡江.胃癌癌組織中p27與cyclinD1的表達(dá)及臨床意義[J].福建醫(yī)藥雜志,2017,39(5):50.

備注/Memo

備注/Memo:
1 通信作者，Email:[email protected]
更新日期/Last Update: 2023-04-15